Department of Pharmacy, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, E-302, Toronto, ON, M4N 3M5, Canada.
Present Address: Grandview Medical Centre Family Health Team, 167 Hespeler Rd, Cambridge, ON, N1R 3H7, Canada.
BMC Pediatr. 2019 Sep 6;19(1):318. doi: 10.1186/s12887-019-1676-3.
Although aminoglycosides are routinely used in neonates, controversy exists regarding empiric dosing regimens. The objectives were to determine gentamicin pharmacokinetics in neonates, and develop initial mg/kg dosing recommendations that optimized target peak and trough concentration attainment for conventional and extended-interval dosing (EID) regimens.
Patient demographics and steady-state gentamicin concentration data were retrospectively collected for 60 neonates with no renal impairment admitted to a level III neonatal intensive care unit. Mean pharmacokinetics were calculated and multiple linear regression was performed to determine significant covariates of clearance (L/h) and volume of distribution (L). Classification and regression tree (CART) analysis identified breakpoints for significant covariates. Monte Carlo Simulation (MCS) was used to determine optimal dosing recommendations for each CART-identified sub-group.
Gentamicin clearance and volume of distribution were significantly associated with weight at gentamicin initiation. CART-identified breakpoints for weight at gentamicin initiation were: ≤ 850 g, 851-1200 g, and > 1200 g. MCS identified that a conventional dose of gentamicin 3.5 mg/kg given every 48 h or an EID of 8-9 mg/kg administered every 72 h in neonates weighing ≤ 850 g, and every 24 and 48 h, respectively, in neonates weighing 851-1200 g, provided the best probability of attaining conventional (peak: 5-10 mg/L and trough: ≤ 2 mg/L) and EID targets (peak:12-20 mg/L, trough:≤ 0.5 mg/L). Insufficient sample size in the > 1200 g neonatal group precluded further investigation of this weight category.
This study provides initial gentamicin dosing recommendations that optimize target attainment for conventional and EID regimens in neonates weighing ≤ 1200 g. Prospective validation and empiric dose optimization for neonates > 1200 g is needed.
尽管氨基糖苷类药物在新生儿中常规使用,但在经验性给药方案方面仍存在争议。本研究旨在确定新生儿中庆大霉素的药代动力学,并制定初始 mg/kg 剂量建议,以优化常规和延长间隔(EID)给药方案的目标峰和谷浓度。
回顾性收集了 60 名无肾功能损害的入住三级新生儿重症监护病房的新生儿的患者人口统计学数据和稳态庆大霉素浓度数据。计算平均药代动力学参数,并进行多元线性回归以确定清除率(L/h)和分布容积(L)的显著协变量。分类回归树(CART)分析确定了显著协变量的断点。蒙特卡罗模拟(MCS)用于确定每个 CART 确定的亚组的最佳给药建议。
庆大霉素清除率和分布容积与庆大霉素起始时的体重显著相关。CART 确定的庆大霉素起始时体重的断点为:≤850g、851-1200g 和>1200g。MCS 确定,体重≤850g 的新生儿给予常规剂量 3.5mg/kg,每 48 小时 1 次,或 EID 剂量 8-9mg/kg,每 72 小时 1 次,体重 851-1200g 的新生儿分别给予每 24 小时和 48 小时 1 次,可提供常规(峰:5-10mg/L,谷:≤2mg/L)和 EID 目标(峰:12-20mg/L,谷:≤0.5mg/L)的最佳达标概率。>1200g 新生儿组的样本量不足,无法进一步研究该体重类别。
本研究为体重≤1200g 的新生儿提供了优化常规和 EID 方案目标达标率的初始庆大霉素给药建议。需要对体重>1200g 的新生儿进行前瞻性验证和经验性剂量优化。